Finn SP - Search Results

1

Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer.

O'Sullivan É, Keogh A, Henderson B, Finn SP, Gray SG, Gately K. O'Sullivan É, et al. Among authors: finn sp. Cancers (Basel). 2023 Mar 7;15(6):1635. doi: 10.3390/cancers15061635. Cancers (Basel). 2023. PMID: 36980522 Free PMC article. Review.

2

Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC.

Heavey S, Godwin P, Baird AM, Barr MP, Umezawa K, Cuffe S, Finn SP, O'Byrne KJ, Gately K. Heavey S, et al. Among authors: finn sp. Cancer Biol Ther. 2014 Oct;15(10):1367-77. doi: 10.4161/cbt.29841. Epub 2014 Jul 15. Cancer Biol Ther. 2014. PMID: 25025901 Free PMC article.

3

The emerging role of microRNAs in resistance to lung cancer treatments.

MacDonagh L, Gray SG, Finn SP, Cuffe S, O'Byrne KJ, Barr MP. MacDonagh L, et al. Among authors: finn sp. Cancer Treat Rev. 2015 Feb;41(2):160-9. doi: 10.1016/j.ctrv.2014.12.009. Epub 2014 Dec 23. Cancer Treat Rev. 2015. PMID: 25592062 Review.

4

KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma.

Cregan S, McDonagh L, Gao Y, Barr MP, O'Byrne KJ, Finn SP, Cuffe S, Gray SG. Cregan S, et al. Among authors: finn sp. Int J Oncol. 2016 Mar;48(3):1290-6. doi: 10.3892/ijo.2016.3335. Epub 2016 Jan 13. Int J Oncol. 2016. PMID: 26780987 Free article.

5

Non-coding RNA repertoires in malignant pleural mesothelioma.

Quinn L, Finn SP, Cuffe S, Gray SG. Quinn L, et al. Among authors: finn sp. Lung Cancer. 2015 Dec;90(3):417-26. doi: 10.1016/j.lungcan.2015.11.002. Epub 2015 Nov 10. Lung Cancer. 2015. PMID: 26791801 Review.

6

Lung cancer stem cells: The root of resistance.

MacDonagh L, Gray SG, Breen E, Cuffe S, Finn SP, O'Byrne KJ, Barr MP. MacDonagh L, et al. Among authors: finn sp. Cancer Lett. 2016 Mar 28;372(2):147-56. doi: 10.1016/j.canlet.2016.01.012. Epub 2016 Jan 18. Cancer Lett. 2016. PMID: 26797015 Review.

7

The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?

Joerger M, Finn SP, Cuffe S, Byrne AT, Gray SG. Joerger M, et al. Among authors: finn sp. Expert Opin Ther Targets. 2016 Nov;20(11):1339-1356. doi: 10.1080/14728222.2016.1206891. Epub 2016 Jul 11. Expert Opin Ther Targets. 2016. PMID: 27353429 Review.

8

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?

Gray SG, Cuffe S, Finn SP. Gray SG, et al. Among authors: finn sp. J Thorac Oncol. 2016 Nov;11(11):e142-e144. doi: 10.1016/j.jtho.2016.07.025. J Thorac Oncol. 2016. PMID: 27770977 Free article. No abstract available.

9

Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma.

Cregan S, Breslin M, Roche G, Wennstedt S, MacDonagh L, Albadri C, Gao Y, O'Byrne KJ, Cuffe S, Finn SP, Gray SG. Cregan S, et al. Among authors: finn sp. Int J Oncol. 2017 Mar;50(3):1044-1052. doi: 10.3892/ijo.2017.3870. Epub 2017 Feb 9. Int J Oncol. 2017. PMID: 28197626

10

Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells.

Heery R, Finn SP, Cuffe S, Gray SG. Heery R, et al. Among authors: finn sp. Cancers (Basel). 2017 Apr 21;9(4):38. doi: 10.3390/cancers9040038. Cancers (Basel). 2017. PMID: 28430163 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

106 results

Search Page